GlassScriptPhysician profile
Amanda Christian
NPI 1245674167
$2,648.49
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $302 · 2021: $973 · 2022: $645 · 2023: $246 · 2024: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $839.32 | 2019-2023 | Lo Loestrin Fe, Orilissa, Ubrelvy |
| Therapeuticsmd, INC. | $291.74 | 2019-2022 | |
| Exeltis, USA INC. | $133.37 | 2019-2022 | |
| Daiichi Sankyo INC. | $130.06 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $106.81 | 2023 | |
| Sumitomo Pharma America, INC. | $102.11 | 2024 | Myfembree |
| Coopersurgical, INC. | $100.00 | 2020 | |
| Merck Sharp & Dohme LLC | $98.38 | 2019-2021 | |
| Evofem Biosciences, INC. | $79.78 | 2020-2021 | |
| Pfizer INC. | $74.58 | 2021-2022 | |
| Organon LLC | $65.28 | 2022-2024 | |
| Hologic Sales and Service, LLC | $63.10 | 2020-2024 | Acessa Provu System, Thinprep 2000 Processor, Aptima |
| Astellas Pharma US INC | $58.16 | 2024 | Veozah |
| Mylan Pharmaceuticals INC. | $52.67 | 2021 | |
| Intuitive Surgical, INC. | $51.88 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Meditrina | $44.27 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.86 | 2022-2023 | Trintellix |
| Davol INC. | $33.05 | 2022 | |
| Lupin INC. | $30.73 | 2019 | |
| Medtronic, INC. | $29.18 | 2021-2022 | |
| Amgen INC. | $26.60 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.24 | 2024 | |
| Incyte Corporation | $20.94 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.65 | 2023 | |
| Allergan, INC. | $20.48 | 2020 | |
| Millicent US INC | $19.29 | 2023 | Femring, Intrarosa |
| Lilly USA, LLC | $19.08 | 2024 | Zepbound, Jardiance |
| Avion Pharmaceuticals | $17.34 | 2023 | Balcoltra |
| Agile Therapeutics, INC. | $16.52 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.15 | 2022 | |
| Ethicon US, LLC | $13.48 | 2020 | |
| Duchesnay USA Incorporated | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Christian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.